UpGuard's Cyber Security Ratings range from 0 to 950. The higher the score, the more likely Aerie Pharmaceuticals is implementing good security practices.
Aerie Pharmaceuticals Inc. (NASDAQ: AERI) is a publicly traded, clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.
This report shows a preliminary security rating for Aerie Pharmaceuticals. UpGuard scans billions of digital assets daily, in depth, across thousands of vectors. Data leak detection, vulnerability scanning and identity breach detection are just some of the advanced capabilities offered by the UpGuard platform.Get a deeper scan →
Read more about the latest issues in cybersecurity
Defense in depth is a cyber security strategy that uses a series of layered, redundant defensive ...
The CIS Critical Security Controls are a prioritized set of actions for cybersecurity that form a ...
Compare Aerie Pharmaceuticals's security performance with other companies